IMU Biosciences, a biotechnology company focused on decoding the immune system at unprecedented resolution and scale, announced that it has expanded its Series A financing to more than $53 million (£40 million) through an oversubscribed round co-led by IQ Capital and Molten Ventures, with support from the British Business Bank, Meltwind, and existing investors.
The company said it has now raised a total of $60 million (£45 million) to support its mission of transforming how diseases are understood, diagnosed, and treated. The latest funding will be used to expand operations, strengthen its clinical platform and infrastructure, and advance multiple clinical programs.
IMU has developed what it describes as the world’s largest immune dataset, which is expected to scale to more than 25,000 individuals in 2026. The company combines high-fidelity multi-omic analysis with proprietary machine learning technology to analyze more than 100 million immune data points from a single blood sample, creating a detailed picture of the immune system at clinical scale.
By leveraging this dataset and analytical platform, IMU aims to establish a universal standard for immune profiling. The company believes its approach can help uncover new immune mechanisms, identify precision treatment strategies, monitor disease progression and treatment response, and predict patient suitability and effectiveness for specific therapies.
The newly raised capital will also support the advancement of several clinical initiatives, including the company’s Stem Cell Transplant Program, Solid Organ Transplant Program, and MANIFEST, a UK-based research consortium focused on understanding patient responses to cancer immunotherapies.
IMU was founded by a team of experimental immunologists and computational biologists with backgrounds at the Francis Crick Institute and King’s College London. The company is developing applications across immune-mediated diseases and therapeutic areas, including transplantation and immuno-oncology.
KEY QUOTES:
“We are delighted to announce IMU’s fundraise, which will allow us to expand our operations and develop our platform whilst continuing to deploy our groundbreaking technology across our clinical programmes as we work to fundamentally change how we understand, diagnose, and treat disease.
Despite the immune system’s profound importance on all aspects of our health, the system as a whole remains poorly understood – obscured by tools that are fragmented, mechanistic and low-resolution. With the largest immune system dataset globally and proprietary technology, IMU is uniquely positioned to fuel discoveries, devise treatments and empower clinicians; improving outcomes for patients across the full spectrum of human health and disease.”
Dr. John Baker, Chief Executive Officer, IMU Biosciences
“When we first invested in IMU in 2024, we believed deep immune profiling combined with AI could unlock something genuinely transformative in precision medicine. Our participation in this round reflects what we’ve seen since: a team that executes and a platform that delivers. The immune system sits at the heart of almost every disease; a company that can interrogate it at this resolution has the potential to redefine how we match the right treatment to the right patient at the right time.
We’re proud to be IMU’s largest shareholder and delighted to welcome IQ Capital and the British Business Bank as investors to the round, their support is a further corroboration of what IMU is building. We’re excited about what comes next.”
Dr. Inga Deakin, Partner, Molten Ventures
“We’re thrilled to support IMU on the next step in their journey as a co-lead investor within this latest funding round. With the world’s largest immune dataset and proprietary machine learning analytics, IMU is pioneering research to realise the huge value of health data, creating better insights for clinicians and improved outcomes for patients. We are proud to be a part of the company’s next phase, and are excited to see what the company is able to accomplish as it grows and develops its technology.”
Dr. Alex Wilson, Partner, IQ Capital
“IMU represents a rare combination of proprietary data scale and deep biological insight. By generating an unprecedented, high-resolution view of the human immune system, the company is creating a foundational platform with the potential to transform how disease is understood and treated. We are excited to support the team as they scale their platform here in the UK and translate this capability into meaningful impact for patients.”
Dr. Carmine Circelli, Senior Investment Director, Life Sciences, British Business Bank
